In a recent transaction on August 15, Sheena Jonathan, co-founder of Natera, Inc. (NASDAQ:), a leading personalized genetic testing and diagnostics company, sold a significant number of shares of the company. The transaction involved the sale of 12,000 shares of common stock at an average price of $121.01, for a total value of approximately $1.45 million.

The shares were sold as part of a prearranged trading plan under Rule 10b5-1, which allows company insiders to set up a trading plan in advance to avoid allegations of insider trading. The prices at which the shares were sold ranged from $121.00 to $121.03, according to the filing. Additional details on the exact number of shares sold at each price within that range are available upon request.

Following the sale, Jonathan still holds a significant stake in Natera. She directly holds 287,441 shares. In addition, there are interests for the benefit of Jonathan’s minor children, amounting to 68,582 shares in the Caraluna 1 Trust and an equal number in the Caraluna 2 Trust. However, she has disclaimed beneficial ownership of these shares, stating that they are not under her direct control.

Natera’s stock performance and insider transactions are closely watched by investors as they can provide insight into the health of the company and the confidence of executives and directors in its future prospects. Jonathan’s recent transaction follows Securities and Exchange Commission guidelines on insider trading and reporting.

Investors and the market will likely continue to monitor the trading activity of Natera’s insiders for clues about the company’s direction and the mood of the leadership team.

More current news: Natera Inc . has announced a significant increase in its revenue and volume growth for the second quarter of 2024. The company reported a 12% sequential increase in revenue over the first quarter and a 58% increase over the same quarter last year. Natera also raised its full-year revenue guidance to approximately $1.5 billion, with an expected gross margin of 55%. These numbers come alongside record levels of test volumes and an increase in average selling prices.

In addition, the National Kidney Foundation has endorsed genetic testing for chronic kidney disease, supporting Natera’s Renasight test. Signatera’s clinical volumes have also grown positively, particularly in colorectal and breast cancer. Despite the delay in submitting the ALTAIR study to ESMO and the non-renewal of the partnership with Foundation Medicine, Natera expects revenue growth of 40% compared to 2023 and expects a modest sequential improvement in Signatera’s ASP in the second half of the year.

In addition, the company plans to deliver steady sequential growth in volume and revenue and invest in usability and product improvements. These recent developments indicate Natera’s robust performance and strategic focus on expanding its product offerings, particularly in the areas of oncology and organ health.

InvestingPro Insights

Given the recent insider trading activity at Natera, Inc. (NASDAQ:NTRA), investors are keen to understand the company’s financial health and future prospects. According to data from InvestingPro, Natera has a market capitalization of $15.34 billion, reflecting a significant presence in the genetic testing industry. The company’s revenue has shown impressive growth, with an increase of 46.13% over the trailing twelve months to Q2 2024 and an even more notable quarterly revenue growth of 58.13% in Q2 2024.

Despite these strong growth numbers, Natera currently operates at a negative P/E ratio of -50.73 and has not been profitable over the last twelve months. This is underlined by an operating profit margin of -23.06% for the same period. However, the company’s gross profit margin is a healthy 53.85%, indicating robust profitability in its core services and products.

InvestingPro Tips highlights that four analysts have recently upgraded their earnings estimates for the upcoming period, indicating a possible improvement in Natera’s financial performance. In addition, the company’s cash and cash equivalents exceed its short-term obligations, indicating a solid liquidity position. It is also worth noting that Natera is trading near its 52-week high, with the price at 99.75% of that peak and a substantial one-week total price return of 8.21%. These metrics could signal investor confidence and a positive market reaction to the company’s growth trajectory.

For investors who want a more in-depth analysis, InvestingPro offers additional insights. In total, 14 InvestingPro tips are available, including perspectives on the company’s debt levels, profitability expectations and dividend policy. Visit https://www.investing.com/pro/NTRA for a comprehensive set of tips and real-time data to help you with your Natera, Inc. investment decisions.

This article was created with the help of AI and reviewed by an editor. For more information, see our Terms and Conditions.